## **Core Concept**
The treatment of Hepatitis C Virus (HCV) infection has evolved significantly with the introduction of direct-acting antivirals (DAAs). The goal of treatment is to achieve sustained virological response (SVR), which is defined as undetectable levels of HCV RNA 12 weeks after completing treatment.

## **Why the Correct Answer is Right**
The correct answer involves a combination of DAAs that target different stages of the HCV life cycle. The most commonly recommended regimen for most genotypes is a combination of **sofosbuvir** (a nucleotide polymerase inhibitor) and **ledipasvir** (an NS5A inhibitor). This combination is highly effective, achieving SVR rates of over 90% in many patients. **Sofosbuvir/ledipasvir** is considered a first-line treatment for several HCV genotypes.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not specify a currently recommended regimen for HCV treatment.
- **Option B:** This option might include drugs that are not used together as a standard regimen or might be outdated.
- **Option D:** This option could include drugs that are not typically used for HCV treatment or are less effective compared to the current standard of care.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the treatment of HCV is genotype-dependent, and the choice of regimen can vary based on factors such as the patient's genotype, previous treatment history, and the presence of cirrhosis. However, **sofosbuvir/ledipasvir** is a widely used and effective combination for several genotypes.

## **Correct Answer:** C. Sofosbuvir/Ledipasvir.